MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$253,766K
Proceeds from employee
stock purchase plan
$372K
Sales of marketable
securities
$57,892K
Proceeds from exercise of
common stock options
$4K
Net cash provided by
(used in) investing...
$45,013K
Net cash provided by
financing activities
$44K
Canceled cashflow
$266,645K
Canceled cashflow
$332K
Net increase in
cash, cash...
-$132,174K
Canceled cashflow
$45,057K
Non-cash interest
expense on deferred...
$38,208K
Prepaid expenses and
other assets
-$19,350K
Stock-based compensation
$14,008K
Depreciation and
amortization
$7,324K
Non-cash lease expenses
$5,884K
Accounts receivable
-$4,639K
Accrued expenses and
other liabilities
$3,552K
Accrued compensation
$1,737K
Impairment charges
$1,694K
Other
-$571K
Purchases of marketable
securities
$264,950K
Purchases of equipment and
leasehold improvements
$1,695K
Taxes paid related to
net share...
$332K
Net cash used in
operating activities
-$177,231K
Canceled cashflow
$96,967K
Income tax expense
-$93K
Net loss
-$191,086K
Canceled cashflow
$93K
Deferred revenue
-$69,729K
Change in operating
lease liability
-$7,480K
Accretion of discount on
marketable securities
$3,435K
Accounts payable
-$2,468K
Loss before
provision for income taxes
-$191,179K
Revenue
$102,484K
Loss from operations
-$158,367K
something is missing
-$32,812K
Canceled cashflow
$102,484K
Operating expenses
$260,851K
Back
Back
Cash Flow
source: myfinsight.com
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)